Baisios

Baisios (Beijing) Biotechnology Co., Ltd., established in 2008, is a national high-tech enterprise based in Beijing's Fengtai Science and Technology Park specializing in biomedical technology and biopharmaceutical research and development. The company focuses on developing and commercializing advanced biological treatments, with a core emphasis on cancer immunotherapy.

The firm has established a significant R&D presence, including a team of over 30 members, a majority holding postgraduate degrees, and standard GMP clean workshops. Its research covers clinical medicine, molecular biology, and immunology. Baisios collaborates with national and international institutions such as the McMaster University Immunology Research Centre in Canada and the Institute of Biophysics at the Chinese Academy of Sciences. Its business model involves the research, development, and subsequent transformation of mature technologies into products for clients to address their R&D challenges.

Baisios's product and technology portfolio is centered on oncology and includes tumor vaccines (HSPPC-96, DC vaccines), various cell immunotherapy technologies (NK, NKT, DC-CIK, TIL, CAR-T), and biotherapeutic drugs like monoclonal antibodies. The company has successfully converted some of these technologies into commercial products, such as processing kits for DC, DC-CIK, NK, and TIL cells, which it markets to other research and clinical entities. The company is also actively involved in establishing industry standards, having co-founded a professional committee for quality control in cell therapy.

Keywords: cell immunotherapy, biopharmaceutical, cancer immunotherapy, oncology, biomedical technology, tumor vaccines, CAR-T, NK cell therapy, DC-CIK, TIL therapy, monoclonal antibodies, biotherapeutic drugs, clinical research, drug development, molecular biology, GMP, life sciences, R&D services, cell processing kits, tumor immunology